GlaxoSmithKline (LON:GSK) has been given a GBX 1,820 ($23.78) target price by investment analysts at HSBC in a research report issued on Thursday. The firm presently has a “buy” rating on the stock. HSBC’s target price would suggest a potential upside of 26.62% from the stock’s previous close.
A number of other research analysts also recently commented on GSK. Kepler Capital Markets reissued a “hold” rating on shares of GlaxoSmithKline in a research report on Tuesday. Liberum Capital reissued a “hold” rating on shares of GlaxoSmithKline in a research report on Tuesday. Deutsche Bank reissued a “hold” rating and issued a GBX 1,525 ($19.93) price objective on shares of GlaxoSmithKline in a research report on Tuesday. Credit Suisse Group set a GBX 1,600 ($20.91) price objective on shares of GlaxoSmithKline and gave the company a “neutral” rating in a research report on Tuesday. Finally, UBS Group reissued a “buy” rating and issued a GBX 1,700 ($22.21) price objective on shares of GlaxoSmithKline in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and eight have issued a buy rating to the company’s stock. GlaxoSmithKline presently has a consensus rating of “Hold” and an average target price of GBX 1,512.99 ($19.77).
Shares of GSK opened at GBX 1,437.40 ($18.78) on Thursday. GlaxoSmithKline has a one year low of GBX 1,235.20 ($16.14) and a one year high of GBX 1,724.50 ($22.53).
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Featured Article: Is it better to buy a fund with a higher or lower NAV?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.